1887

Abstract

We describe associations between death from invasive pneumococcal disease (IPD) and particular serogroups and sequence types (STs) determined by multilocus sequence typing (MLST) using data from Scotland. All IPD episodes where blood or cerebrospinal fluid (CSF) culture isolates were referred to the Scottish Haemophilus, Legionella, Meningococcal and Pneumococcal Reference Laboratory (SHLMPRL) from January 1992 to February 2007 were matched to death certification records by the General Register Office for Scotland. This represented 5959 patients. The median number of IPD cases in Scotland each year was 292. Deaths, from any cause, within 30 days of pneumococcal culture from blood or CSF were considered to have IPD as a contributing factor. Eight hundred and thirty-three patients died within 30 days of culture of e from blood or CSF [13.95 %; 95 % confidence interval (13.10, 14.80)]. The highest death rates were in patients over the age of 75. Serotyping data exist for all years but MLST data were only available from 2001 onward. The risk ratio of dying from infection due to particular serogroups or STs compared to dying from IPD due to all other serogroups or STs was calculated. Fisher’s exact test with Bonferroni adjustment for multiple testing was used. Age adjustment was accomplished using the Cochran–Mantel–Haenszel test and 95 % confidence intervals were reported. Serogroups 3, 11 and 16 have increased probability of causing fatal IPD in Scotland while serogroup 1 IPD has a reduced probability of causing death. None of the 20 most common STs were significantly associated with death within 30 days of pneumococcal culture, after age adjustment. We conclude that there is a stronger association between a fatal outcome and pneumococcal capsular serogroup than there is between a fatal outcome and ST.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.028803-0
2011-06-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/6/793.html?itemId=/content/journal/jmm/10.1099/jmm.0.028803-0&mimeType=html&fmt=ahah

References

  1. Alanee S. R. J., McGee L., Jackson D., Chiou C. C., Feldman C., Morris A. J., Ortqvist A., Rello J., Luna C. M. et al. 2007; Association of serotypes of Streptococcus pneumoniae with disease severity and outcome in adults: an international study. Clin Infect Dis 45:46–51 [View Article][PubMed]
    [Google Scholar]
  2. Aspa J., Rajas O., Rodriguez de Castro F., Huertas M. C., Borderías L., Cabello F. J., Tábara J., Hernández-Flix S., Martinez-Sanchis A., Torres A. Pneumococcal Pneumonia in Spain Study Group 2006; Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 27:1010–1019[PubMed]
    [Google Scholar]
  3. Austrian R., Gold J. 1964; Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 60:759–776[PubMed] [CrossRef]
    [Google Scholar]
  4. Avery O. T., Chickering H. T., Cole R., Dochez A. R. 1917 Acute Lobar Pneumonia; Prevention and Serum TreatmentRockefeller Institute Medical Research Monograph 7 New York: Rockefeller Institute;
    [Google Scholar]
  5. Baddour L. M., Yu V. L., Klugman K. P., Feldman C., Ortqvist A., Rello J., Morris A. J., Luna C. M., Snydman D. R. et al. 2004; Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 170:440–444 [View Article][PubMed]
    [Google Scholar]
  6. Berg S., Trollfors B., Persson E., Backhaus E., Larsson P., Ek E., Claesson B. E., Jonsson L., Rådberg G. et al. 2006; Serotypes of Streptococcus pneumoniae isolated from blood and cerebrospinal fluid related to vaccine serotypes and to clinical characteristics. Scand J Infect Dis 38:427–432 [View Article][PubMed]
    [Google Scholar]
  7. Blake F. G. 1931; Observations on pneumococcus type III pneumonia. Ann Intern Med 5:673–686 [CrossRef]
    [Google Scholar]
  8. Brueggemann A. B., Griffiths D. T., Meats E., Peto T., Crook D. W., Spratt B. G. 2003; Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 187:1424–1432 [View Article][PubMed]
    [Google Scholar]
  9. Carrol E. D., Mankhambo L. A., Corless C., Guiver M. 2008; Bacteremia is associated with a worse outcome in pneumococcal meningitis. J Infect Dis 198:626–627 [View Article][PubMed]
    [Google Scholar]
  10. Cecil R. L., Baldwin H. S., Larsen N. P. 1927; Lobar pneumonia. A clinical and bacteriological study of two thousand typed cases. Arch Intern Med 40:253–280 [CrossRef]
    [Google Scholar]
  11. Chen C. J., Lin C. L., Chen Y. C., Wang C. W., Chiu C. H., Lin T. Y., Huang Y. C. 2009; Host and microbiologic factors associated with mortality in Taiwanese children with invasive pneumococcal diseases, 2001 to 2006. Diagn Microbiol Infect Dis 63:194–200 [View Article][PubMed]
    [Google Scholar]
  12. Clarke S. C., Diggle M. A. 2002; Automated PCR/sequence template purification. Mol Biotechnol 21:221–224 [View Article][PubMed]
    [Google Scholar]
  13. Cooke B., Smith A., Diggle M., Lamb K., Robertson C., Inverarity D., Jefferies J., Edwards G., Mitchell T. et al. 2010; Antibiotic resistance in invasive Streptococcus pneumoniae isolates identified in Scotland between 1999 and 2007. J Med Microbiol 59:1212–1218 [View Article][PubMed]
    [Google Scholar]
  14. Cowan J., Harrington A. W., Cruikshank R., Cuthbertson D. P., Fleming J. 1932; Treatment of lobar pneumonia by Felton’s serum. Lancet ii:8–11 [View Article]
    [Google Scholar]
  15. Diggle M. A., Clarke S. C. 2002; Rapid assignment of nucleotide sequence data to allele types for multi-locus sequence analysis (MLSA) of bacteria using an adapted database and modified alignment program. J Mol Microbiol Biotechnol 4:515–517[PubMed]
    [Google Scholar]
  16. Easton D. F., Peto J., Babiker A. G. A. G. 1991; Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group. Stat Med 10:1025–1035 [View Article][PubMed]
    [Google Scholar]
  17. Engelhard D., Pomeranz S., Gallily R., Strauss N., Tuomanen E. 1997; Serotype-related differences in inflammatory response to Streptococcus pneumoniae in experimental meningitis. J Infect Dis 175:979–982 [View Article][PubMed]
    [Google Scholar]
  18. Enright M. C., Spratt B. G. 1998; A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 144:3049–3060 [View Article][PubMed]
    [Google Scholar]
  19. Garau J., Calbo E. 2007; Capsular types and predicting patient outcomes in pneumococcal bacteremia. Clin Infect Dis 45:52–54 [View Article][PubMed]
    [Google Scholar]
  20. Guimbao Bescós J., Vergara Ugarriza A., Aspiroz Sancho C., Aldea Aldanondo M. J., Lázaro M. A., Alberto M. J., Varona López W., Toledo M. 2003; [Streptococcus pneumoniae transmission in a nursing home: analysis of an epidemic outbreak]. Med Clin (Barc) 121:48–52 (in Spanish) [PubMed] [CrossRef]
    [Google Scholar]
  21. Harboe Z. B., Thomsen R. W., Riis A., Valentiner-Branth P., Christensen J. J., Lambertsen L., Krogfelt K. A., Konradsen H. B., Benfield T. L. 2009; Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 6:e1000081 [View Article][PubMed]
    [Google Scholar]
  22. Huss A., Scott P., Stuck A. E., Trotter C., Egger M. 2009; Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 180:48–58[PubMed] [CrossRef]
    [Google Scholar]
  23. Inostroza J., Vinet A. M., Retamal G., Lorca P., Ossa G., Facklam R. R., Sorensen R. U. 2001; Influence of patient age on Streptococcus pneumoniae serotypes causing invasive disease. Clin Diagn Lab Immunol 8:556–559[PubMed]
    [Google Scholar]
  24. Jansen A. G. S. C., Rodenburg G. D., van der Ende A., van Alphen L., Veenhoven R. H., Spanjaard L., Sanders E. A. M., Hak E. 2009; Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 49:e23–e29 [View Article][PubMed]
    [Google Scholar]
  25. Jefferies J. M. C., Clarke S. C., Diggle M. A., Smith A., Dowson C., Mitchell T. 2003; Automated pneumococcal MLST using liquid-handling robotics and a capillary DNA sequencer. Mol Biotechnol 24:303–308 [View Article][PubMed]
    [Google Scholar]
  26. Jefferies J. M., Smith A. J., Edwards G. F. S., McMenamin J., Mitchell T. J., Clarke S. C. 2010; Temporal analysis of invasive pneumococcal clones from Scotland illustrates fluctuations in diversity of serotype and genotype in the absence of pneumococcal conjugate vaccine. J Clin Microbiol 48:87–96 [View Article][PubMed]
    [Google Scholar]
  27. Kendrick S., Clarke J. 1993; The Scottish record linkage system. Health Bull (Edinb) 51:72–79[PubMed]
    [Google Scholar]
  28. Kyaw M. H., Christie P., Clarke S. C., Mooney J. D., Ahmed S., Jones I. G., Campbell H. 2003; Invasive pneumococcal disease in Scotland, 1999–2001: use of record linkage to explore associations between patients and disease in relation to future vaccination policy. Clin Infect Dis 37:1283–1291 [View Article][PubMed]
    [Google Scholar]
  29. Lamb K., Diggle M., Inverarity D., Jefferies J. M., Edwards G., McMenamin J., Mitchell T. J., Clarke S. C. 2008; Trends in serotypes and multi locus sequence types (MLST) among cases of invasive pneumococcal disease (IPD) in Scotland.. In 6th International Symposium on Pneumococci and Pneumococcal Diseases Reykjavik, Iceland, P1-012
    [Google Scholar]
  30. Macfarlane J. T., Finch R. G., Ward M. J., Macrae A. D. 1982; Hospital study of adult community-acquired pneumonia. Lancet 2:255–258 [View Article][PubMed]
    [Google Scholar]
  31. Maddox J. M., Winter J. H. 2003; Pneumococcal bacteraemia: clinical and microbiological epidemiology in Dundee, Scotland. J Infect 47:12–18 [View Article][PubMed]
    [Google Scholar]
  32. Martens P., Worm S. W., Lundgren B., Konradsen H. B., Benfield T. 2004; Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infect Dis 4:21 [View Article][PubMed]
    [Google Scholar]
  33. Martin D. R., Brett M. S. 1996; Pneumococci causing invasive disease in New Zealand, 1987–94: serogroup and serotype coverage and antibiotic resistances. N Z Med J 109:288–290[PubMed]
    [Google Scholar]
  34. Martínez J. A., Horcajada J. P., Almela M., Marco F., Soriano A., García E., Marco M. A., Torres A., Mensa J. 2003; Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 36:389–395 [View Article][PubMed]
    [Google Scholar]
  35. Metersky M. L., Ma A., Houck P. M., Bratzler D. W. 2007; Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 131:466–473 [View Article][PubMed]
    [Google Scholar]
  36. Mizrachi-Nebenzahl Y., Lifshitz S., Teitelbaum R., Novick S., Levi A., Benharroch D., Ling E., Dagan R. 2003; Differential activation of the immune system by virulent Streptococcus pneumoniae strains determines recovery or death of the host. Clin Exp Immunol 134:23–31 [View Article][PubMed]
    [Google Scholar]
  37. Mooney J. D., Weir A., McMenamin J., Ritchie L. D., Macfarlane T. V., Simpson C. R., Ahmed S., Robertson C., Clarke S. C. 2008; The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect Dis 8:53 [View Article][PubMed]
    [Google Scholar]
  38. Ortqvist A., Kalin M., Julander I., Mufson M. A. 1993; Deaths in bacteremic pneumococcal pneumonia. A comparison of two populations – Huntington, WVa, and Stockholm, Sweden. Chest 103:710–716 [View Article][PubMed]
    [Google Scholar]
  39. Rahav G., Toledano Y., Engelhard D., Simhon A., Moses A. E., Sacks T., Shapiro M. 1997; Invasive pneumococcal infections. A comparison between adults and children. Medicine (Baltimore) 76:295–303 [View Article][PubMed]
    [Google Scholar]
  40. R Development Core Team 2008; R: a Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; Available at http://www.r-project.org
    [Google Scholar]
  41. Rückinger S., von Kries R., Siedler A., van der Linden M. 2009; Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatr Infect Dis J 28:118–122 [View Article][PubMed]
    [Google Scholar]
  42. Sandgren A., Albiger B., Orihuela C. J., Tuomanen E., Normark S., Henriques-Normark B. 2005; Virulence in mice of pneumococcal clonal types with known invasive disease potential in humans. J Infect Dis 192:791–800 [View Article][PubMed]
    [Google Scholar]
  43. Scott J. A. G. 2007; The preventable burden of pneumococcal disease in the developing world. Vaccine 25:2398–2405 [View Article][PubMed]
    [Google Scholar]
  44. Shapiro E. D., Austrian R. 1994; Serotypes responsible for invasive Streptococcus pneumoniae infections among children in Connecticut. J Infect Dis 169:212–214[PubMed] [CrossRef]
    [Google Scholar]
  45. Sjöström K., Spindler C., Ortqvist A., Kalin M., Sandgren A., Kühlmann-Berenzon S., Henriques-Normark B. 2006; Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 42:451–459 [View Article][PubMed]
    [Google Scholar]
  46. Smart L. E. 1986; Serotyping of Streptococcus pneumoniae strains by coagglutination. J Clin Pathol 39:328–331 [View Article][PubMed]
    [Google Scholar]
  47. Sullivan C. B., Jefferies J. M., Diggle M. A., Clarke S. C. 2006; Automation of MLST using third-generation liquid-handling technology. Mol Biotechnol 32:219–226 [View Article][PubMed]
    [Google Scholar]
  48. Waterer G. W., Somes G. W., Wunderink R. G. 2001; Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 161:1837–1842 [View Article][PubMed]
    [Google Scholar]
  49. Weinberger D. M., Harboe Z. B., Sanders E. A. M., Ndiritu M., Klugman K. P., Rückinger S., Dagan R., Adegbola R., Cutts F. et al. 2010; Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 51:692–699 [View Article][PubMed]
    [Google Scholar]
  50. Weiss K., Low D. E., Cortes L., Beaupre A., Gauthier R., Gregoire P., Legare M., Nepveu F., Thibert D. et al. 2004; Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 11:589–593[PubMed]
    [Google Scholar]
  51. WHO 2007; Pneumococcal conjugate vaccine for childhood immunization – WHO position paper. Wkly Epidemiol Rec 82:93–104[PubMed]
    [Google Scholar]
  52. Yu V. L., Chiou C. C. C., Feldman C., Ortqvist A., Rello J., Morris A. J., Baddour L. M., Luna C. M., Snydman D. R. et al. 2003; An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 37:230–237 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.028803-0
Loading
/content/journal/jmm/10.1099/jmm.0.028803-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error